Blog
RSS FeedPosted by Michael Wonder on 16 Jan 2020
Novavax granted fast track designation for NanoFlu in older adults
15 January 2020 - Novavax today announced that the U.S. FDA has granted fast track designation for NanoFlu, its recombinant quadrivalent ...
Posted by Michael Wonder on 10 Jan 2020
Meissa Vaccines receives U.S. FDA fast track designation for respiratory syncytial virus vaccine, MV-012-968
10 January 2020 - Meissa Vaccines announced today that the U.S. FDA has granted fast track designation to MV-012-968, an ...
Posted by Michael Wonder on 08 Jan 2020
PBAC – 2019 in review
8 January 2020 - The PBAC considered 188 submissions in 2019. ...
Posted by Michael Wonder on 07 Jan 2020
Summary of submissions and outcomes from the November 2019 PBAC meeting
7 January 2020 - Analysis and insights from the November 2019 PBAC meeting. ...
Posted by Michael Wonder on 24 Dec 2019
Meningococcal B vaccine rejected for inclusion on free schedule
22 December 2019 - It is the most common strain of deadly meningococcal disease, but the vaccine for the B strain ...
Posted by Michael Wonder on 20 Dec 2019
First FDA approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response
19 December 2019 - The U.S. FDA announced today the approval of Ervebo, the first FDA approved vaccine for the prevention ...
Posted by Michael Wonder on 16 Dec 2019
Flawed forecasting? Why New Zealand ran out of MMR vaccine
16 December 2019 - PHARMAC's forecast for how many doses of MMR vaccine would be needed for 2019 was around ...
Posted by Michael Wonder on 13 Dec 2019
Y-mAbs’ GD2-GD3 vaccine granted rare paediatric disease designation
12 December 2019 - Y-mAbs Therapeutics today announced that its GD2-GD3 vaccine has been granted a rare paediatric disease designation ...
Posted by Michael Wonder on 12 Dec 2019
Seqirus announces Health Canada approval of first cell-based seasonal influenza vaccine
11 December 2019 - Seqirus, a global leader in influenza prevention, announced today that its cell-based quadrivalent influenza vaccine has ...
Posted by Michael Wonder on 12 Dec 2019
2019-20 cost recovery implementation statement for PBS/NIP updated for 2018-19 financial outcome
12 December 2019 - The 2019–20 Cost Recovery Implementation Statement for the listing of medicines on the Pharmaceutical Benefits Scheme and ...
Posted by Michael Wonder on 26 Nov 2019
Plans for measles vaccinations to be distributed back through PHARMAC
26 November 2019 - Measles vaccinations in the south will likely go back to being distributed by PHARMAC after being ...
Posted by Michael Wonder on 22 Nov 2019
The life improvement value: a new measure of cost-efficiency
23 November 2019 - The decision not to make zoster vaccination available to people older than 79 years1 was based on ...
Posted by Michael Wonder on 15 Nov 2019
Meningitis Foundation calls for PHARMAC to protect everyone
15 November 2019 - Following PHARMAC’s announcement stating the meningococcal ACWY vaccine will be available free from next month for ...
Posted by Michael Wonder on 14 Nov 2019
PHARMAC widening access to the meningococcal ACWY vaccine
14 November 2019 - The meningococcal ACWY vaccine will be available free from next month for young people in close ...
Posted by Michael Wonder on 12 Nov 2019
Merck’s Ervebo [Ebola Zaire vaccine (rVSVΔG-ZEBOV-GP) live] granted conditional approval in the European Union
12 November 2019 - Authorisation represents significant advancement in the global response to Ebola. ...